CAR-GPC3 T Cells
Sponsors
CARsgen Therapeutics Co., Ltd., RenJi Hospital, Zhejiang University, Sotio Biotech Inc., Shanghai Ming Ju Biotechnology Co., Ltd.
Conditions
Advanced Hepatocellular CarcinomaHepatic Cell CarcinomaHepatocellular CarcinomaLiver CarcinomaLung Squamous Cell CarcinomaMerkel Cell CarcinomaMyxoid/Round Cell LiposarcomaSquamous Cell Carcinoma of the Lung
Phase 1
Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma
NCT02876978
Start: 2016-03-31End: 2019-04-30Target: 20Updated: 2016-08-24
Chimeric Antigen Receptor T Cells Targeting Glypican-3
CompletedNCT03884751
Start: 2019-08-15End: 2021-12-03Updated: 2022-02-24
4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3
CompletedNCT03980288
Start: 2019-07-23End: 2020-12-30Updated: 2023-01-31
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors
Active, not recruitingNCT05120271
Start: 2022-10-26End: 2042-12-31Updated: 2025-12-05
A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma
NCT06144385
Start: 2022-03-24End: 2024-12-31Target: 20Updated: 2024-01-02
Unknown Phase
CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma
CompletedNCT03146234
Start: 2017-03-17End: 2018-10-18Updated: 2019-08-28
GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma
RecruitingNCT05926726
Start: 2023-01-01End: 2026-12-31Target: 12Updated: 2023-07-03